Mediwound Ltd (NASDAQ:MDWD) saw a significant decline in short interest in the month of November. As of November 29th, there was short interest totalling 114,400 shares, a decline of 16.9% from the November 14th total of 137,700 shares. Based on an average trading volume of 40,500 shares, the short-interest ratio is presently 2.8 days. Approximately 0.7% of the shares of the company are sold short.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Oppenheimer & Co. Inc. lifted its position in Mediwound by 11.0% during the third quarter. Oppenheimer & Co. Inc. now owns 48,600 shares of the biopharmaceutical company’s stock valued at $156,000 after purchasing an additional 4,800 shares in the last quarter. California Public Employees Retirement System lifted its position in Mediwound by 5.8% during the third quarter. California Public Employees Retirement System now owns 211,500 shares of the biopharmaceutical company’s stock valued at $670,000 after purchasing an additional 11,600 shares in the last quarter. Sargent Investment Group LLC lifted its position in Mediwound by 114.8% during the second quarter. Sargent Investment Group LLC now owns 29,000 shares of the biopharmaceutical company’s stock valued at $98,000 after purchasing an additional 15,500 shares in the last quarter. Finally, Marshall Wace LLP purchased a new position in Mediwound during the first quarter valued at $93,000. Institutional investors own 26.19% of the company’s stock.
Shares of MDWD remained flat at $$3.00 during trading hours on Thursday. The company had a trading volume of 54,700 shares, compared to its average volume of 138,271. The company has a debt-to-equity ratio of 0.11, a current ratio of 3.65 and a quick ratio of 3.52. Mediwound has a one year low of $2.55 and a one year high of $6.09. The company has a market cap of $82.62 million, a price-to-earnings ratio of -6.12 and a beta of 0.48. The firm has a 50 day moving average price of $2.95 and a two-hundred day moving average price of $3.21.
Several brokerages recently commented on MDWD. Oppenheimer cut their price objective on Mediwound from $15.00 to $7.00 and set an “outperform” rating for the company in a report on Wednesday, August 14th. Zacks Investment Research raised Mediwound from a “hold” rating to a “buy” rating and set a $3.25 price objective for the company in a report on Wednesday, November 20th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $5.50 price objective on shares of Mediwound in a report on Friday, November 15th.
Mediwound Company Profile
MediWound Ltd., an integrated biopharmaceutical company, focuses on developing, manufacturing, and commercializing novel therapeutics products to address unmet needs. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns in the European Union, Israel, and Argentina.
Recommended Story: Trade Deficit
Receive News & Ratings for Mediwound Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mediwound and related companies with MarketBeat.com's FREE daily email newsletter.